Anthrogenesis Corporation

Celularity Inc.

Anthrogenesis Corproation

Clarity Acquisition II LLC

Xiaokui Zhang

Vanessa R Voskinarian-Berse

Lin Kang

Robert J Hariri

Stewart Abbot

Andrew L Zeitlin

Mohammad A Heidaran

Ajai Pal

Eric Law

Vanessa Voskinarian-Berse

Vanessa A Voskinarian-Berse

Steven Alan Fischkoff

Neerav Dilip Padliya

Kathy Karasiewicz-Mendez

Bhavani Stout

Stephen Jasko

Brian P Murphy

James W Edinger

Uri Herzberg

Bitao Liang

Sascha Dawn Abramson

Vladimir Jankovic

Aleksandar Francki

Jodi P Gurney

Shmuel Yaccoby

Wolfgang Hofgartner

Cynthia Ray

Andy Zeitlin

Keith Wilson

Andrea Nordberg

Katarzyna Karasiewicz-Mendez

Han Myint

Mohamad Hussein

Ivana Djuretic

Philippe Martin

Stacy Herb

Stewart Ernest Abbott

Vanessa Voskinarian-berse

Henry Rendon Barrigan

Steven Jasko

Neerav Dilip Padlina

Provided herein are placental stem cells that exhibit increased survival ('enhanced placental stem cells'), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.

Enhanced placental stem cells and uses thereof

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL-2.

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

Therapy with cells from human placenta and hematopoietic cells

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Method of producing erythrocytes without feeder cells

Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.

Natural killer cells from placenta

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

Methods of generating natural killer cells

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Method of producing erythrocytes

Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.

Treatment of bone-related cancers using placental stem cells

Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.

Enhancement of placental stem cell potency using modulatory RNA molecules

Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or disorder.

Treatment of sarcoidosis using placental stem cells

Growing community of inventors

Livingston, NJ, United States of America

Xiaokui Zhang